Hester Biosciences share price today

Hester Biosciences Ltd's share price was ₹2,312.00 at the close on 4 November 2026. It has been rising for 22 weeks. That is 13.3% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹1,317 and ₹2,478, and at that close it sat 86% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Hester Biosciences Ltd is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 1 week in a row.

Over the last 11 years the share price moved +426% while the NIFTY 500 moved +251%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

4 points in one quarter, revenue fell in the June 2026 quarter and foreign funds (FIIs) cut their stake for 4 quarters in a row.

1. Promoters cut their stake by 9.4 points in one quarter

   From 53.7% to 44.3% in the September 2026 quarter.

2. Revenue fell in the June 2026 quarter

   Revenue was ₹77 crore, -8.3% on a year earlier (₹84 crore), after 2 quarters of growth.

   Why: Revenue fell because the company earned less from Nepal and Africa.

   From the earnings call on 30 Jul 2026.

3. Foreign funds (FIIs) cut their stake for 4 quarters in a row

   From 0.5% to 0.3% of the company by the September 2026 quarter.

For April to June 2026 (the quarter ended 30 June 2026), Hester Biosciences reported revenue of ₹77.0 crore, down 8.3% from ₹84.0 crore a year earlier, and a profit of ₹97.0 crore, up 470.6% from ₹17.0 crore.

Hester Biosciences results: April to June 2026 against a year earlier

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

Hester Biosciences' management discussed these results on a call held on 30 July 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.

Hester Biosciences closed at ₹2,312.00 on 4 November 2026, up 44.3% from ₹1,601.80 a year earlier (7 November 2025) and down 7.4% over five years. Its highest weekly close since March 2016 was ₹3,212.70 on 26 July 2024.

Hester Biosciences share price: then and now

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

562 weekly closes from 11 March 2016 to 4 November 2026.

4 Nov 2026: Hester Biosciences closed at ₹2,312.00, up 0.5% on the week and up 8.0% on the month. Our read, 22 Aug 2026: Hester's standalone business is genuinely improving, poultry grew 48%, standalone operating profit rose 95%, and H9N2 is clearly adding volume. But the consolidated Jun 2026 net profit of 97 Cr is almost entirely an exceptional accounting gain from the Gates Foundation restructuring Hester Africa's loan, not operating earnings. The critical concern is that animal healthcare tender recovery has now been missed for the third time in two years, with management repeating the same 'next quarter' promise without explaining why the previous commitment failed.

Earlier

• 30 Jul 2026: Hester Biosciences held its results call for April to June 2026. Management guided: FY27 priorities are to strengthen biologicals, expand domestic and export penetration, advance R&D, improve manufacturing utilization and maintain operational discipline.
• 14 Jul 2026: ex-date for a dividend of ₹11 a share.
• Results for April to June 2026: Revenue down 8.3% and profit up 470.6% on a year earlier.

Our read of the business

Hester's standalone business is genuinely improving, poultry grew 48%, standalone operating profit rose 95%, and H9N2 is clearly adding volume. But the consolidated Jun 2026 net profit of 97 Cr is almost entirely an exceptional accounting gain from the Gates Foundation restructuring Hester Africa's loan, not operating earnings. The critical concern is that animal healthcare tender recovery has now been missed for the third time in two years, with management repeating the same 'next quarter' promise without explaining why the previous commitment failed.

April to June 2026: Exceptional accounting gain of approximately 74 Cr from Gates Foundation loan amendment inflates consolidated profit to 97 Cr; standalone operating profit actually rose 95% on poultry strength.

Our read after the April to June 2026 results, written 22 August 2026.

Hester Biosciences paid ₹11 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 0.48% at the ₹2,312.00 close on 4 November 2026. The last was a dividend of ₹11 a share, ex-date 14 July 2026.

Hester Biosciences dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here.

Yes. Hester Biosciences Ltd paid out 17% of its profit as dividends in FY26, and it paid a dividend in each of its last 13 reported years.

From the NSE corporate-actions record, read 5 November 2026.

On the call for April to June 2026, held on 30 July 2026, Hester Biosciences' management guided: FY27 priorities are to strengthen biologicals, expand domestic and export penetration, advance R&D, improve manufacturing utilization and maintain operational discipline.

“Our objective is to provide poultry farmers with integrated health solutions that improve farm productivity and disease management rather than viewing disease prevention through a single product approach”Priya Gandhi, on the call for April to June 2026

What management guided

• Delayed PPR and lumpy skin disease government programs are expected to contribute in the next quarter.
• Animal-health tender business is viewed as steady over a broader 1-3 year period despite timing variation, with direct farm and institutional demand being developed.
• Africa will be built quarter-to-quarter toward gradual top-line and bottom-line stabilization.
• BSL3 and fill-finish capacity will be deployed for veterinary products toward optimum utilization; no facility-specific goal was given.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for April to June 2026, 30 July 2026.

What is changing at Hester Biosciences, from the latest results and calls: h9n2 avian influenza vaccine, commercial ramp, animal healthcare tender normalization and fill-finish facility operating leverage.

• H9N2 Avian Influenza Vaccine, Commercial Ramp. H9N2 licensed January to March 2026, now in first full commercial year; poultry growing 48% in April to June 2026 confirming early market acceptance. ⚠ estimate
• Animal Healthcare Tender Normalization. Government PPR and goatpox programs have now been deferred three times; July to September 2026 is the fourth promised recovery date. ⚠ estimate
• Fill-Finish Facility Operating Leverage. Facility capitalized, now at 60-65% utilization; incremental volume from H9N2 and export scale-up flows at high incremental margins. ⚠ estimate
• Africa PPR Program, Long-Duration Option. Tanzania plant profitable; Gates Foundation loan restructured giving balance sheet relief, but the FY28 breakeven goal was silently dropped. ⚠ estimate

We check 16 kinds of change in every company, such as costs spread over more sales, higher-value products, new orders, new regions or falling debt, against its reported numbers and what management said on its calls. Only changes the numbers back are shown.

Our read after the April to June 2026 results, written 22 August 2026.

If animal healthcare quarterly revenue falls below 20 Cr for two consecutive quarters after July to September 2026, meaning the third 'next quarter' promise also fails, the tender normalization thesis is broken, not delayed. That combined with any decline in poultry operating margin below 24% would indicate the current earnings level is a local peak, not a genuine recovery, and the position should be exited.

Each change stops working if

• H9N2 Avian Influenza Vaccine, Commercial Ramp: A competing avian flu vaccine from a larger manufacturer launches in India with better pricing, or HPAI disease incidence drops materially, reducing preventive vaccination demand among private poultry farmers.
• Africa PPR Program, Long-Duration Option: Political instability in Tanzania forces facility closure, or GALVmed funding for the PPR eradication program is reduced or redirected, which would remove the primary institutional demand driver for Africa.

The main risks

• Management Credibility, Five Documented Reversals: Five documented guidance reversals without acknowledgment across four concalls; concall credibility severely impaired. ⚠ estimate
• Government Tender Calendar, Structural vs Cyclical Question: Three consecutive misses raise a structural question: is the tender calendar reliably executing or permanently unreliable? ✓ fact
• Receivables and Cash Conversion Cycle: Debtor days 105 in FY26 (up from 86 in FY25); bad-debt write-offs 6.5 Cr flagged as one-off but need confirmation. ✓ fact
• Exceptional Gain Inflating last 12 months Metrics: Last 12 months EPS of 160 and net profit of 137 Cr include the Gates Foundation exceptional gain, quoting either figure as earnings power is misleading. ✓ fact

Our read after the April to June 2026 results, written 22 August 2026.

When Hester Biosciences reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: Delayed PPR and lumpy skin disease government programs are expected to contribute in the next quarter; check whether Goat Pox vaccine sales return as indicated.

Hester Biosciences is on one of our India lists: Pharma stocks.

Hester Biosciences Ltd earned ₹97.0 Cr of net profit in the Jun 2026 quarter. That quarter includes a one-off gain bigger than its revenue, so the comparison with last year does not reflect normal business. Full-year FY26 profit was ₹57.0 Cr. Over 10 years profit has grown 11.6% a year on average. That is 126.0% of the quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier earned ₹17.0 Cr.

Jun 2026 profit was ₹97.0 Cr, +470.6% on a year earlier. For the full year, FY26 profit was ₹57.0 Cr (+96.6% on the year before).

Read this profit with care: at ₹97.0 Cr it is bigger than the quarter's whole revenue of ₹77.0 Cr. No business earns more than it takes in from sales, so this is a one-off item (for example a debt settlement, a tax write-back or an asset sale), not money the business earned. The underlying business is running at a 29.0% operating margin. The jump on last year, and any P/E built on this profit, come from the one-off, not from a real turn in earnings.

FY26-Q4. revenue ₹100 Cr and profit ₹17 Cr as reported.

FY27-Q1. revenue ₹77 Cr and profit ₹97 Cr as reported.

Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters.

Hester Biosciences Ltd reported ₹77.0 Cr of revenue in the Jun 2026 quarter, −8.3% on the same quarter a year earlier. Over 10 years it has grown 12.7% a year on average. The last full year, FY26, came in at ₹333 Cr. The last four reported quarters add to ₹325 Cr.

Revenue is everything the company billed its customers in the period.

FY26 revenue was ₹333 Cr, +7.1% on the year before.

Recent pace: the last four quarters grew +5.1% on average, against 12.7% a year over the longer run, so this year is growing slower than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +3.8%, against +4.4% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +260.5%, against +155.4% a year (accelerating).

FY26-Q4. revenue ₹100 Cr and profit ₹17 Cr as reported.

FY27-Q1. revenue ₹77 Cr and profit ₹97 Cr as reported.

Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters.

Hester Biosciences Ltd's operating margin was 29.0% in the Jun 2026 quarter, 2.0 percentage points higher than the same quarter a year ago. Across 13 years it has been between 18.0% and 38.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed +2.4 percentage points on the year while gross margin changed +4.6 points. So the gain came mostly from the gross margin, which means input costs and prices charged.

FY26-Q4. revenue ₹100 Cr and profit ₹17 Cr as reported.

FY27-Q1. revenue ₹77 Cr and profit ₹97 Cr as reported.

Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters.

Over the last 3 years, 165% of Hester Biosciences Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹64.0 Cr of operating cash against ₹57.0 Cr of profit. After ₹23.0 Cr of spending on assets, ₹41.0 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason.

What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building.

Hester Biosciences Ltd's customer, stock and supplier day counts come out in the thousands of days on sales this small (₹333 Cr in FY26), so no cash-cycle chart is drawn and this section looks at its spending on assets instead. It spent ₹65.0 Cr on assets over the last 3 years.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Why this happened. Hester Africa has multi-vaccine technology capability from the Tanzania plant and participates in the GALVmed-led VITAL program. Africa generated a large exceptional accounting gain in Q1 FY27 through the Gates Foundation loan amendment, principal reduced from USD 12 million to USD 5 million and interest waived. But the FY28 breakeven commitment confirmed in Nov 2025 was dropped without explanation by May 2026, and management currently describes Africa as a 'formative period' with quarter-to-quarter progress expected. The tax-free status runs through 2030. This remains a long-duration option, not a near-term driver.

Averaged over those years that is 6.5% of FY26 revenue a year.

Spending on assets: ₹65.0 Cr over the last 3 years, against ₹53.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building a little beyond replacing what wears out. Work still in progress is ₹9.0 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Hester Biosciences Ltd's P/E is 37.1×, near the low end of its own history: it has been lower only 28% of the time. Its usual P/E (the middle reading) is 46.8×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.